Targeting Integrin αvβ6 for PET Imaging in Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the use of a new PET imaging probe, 68Ga-Trivehexin, which targets integrin αvβ6, a protein specifically expressed in malignant tumors. The study aims to evaluate the diagnostic and staging capabilities of this probe in patients with newly diagnosed malignant tumors, including non-small cell lung cancer and breast cancer. Participants will undergo PET/CT scans to assess the probe's effectiveness compared to traditional imaging methods. The research seeks to improve early diagnosis and treatment evaluation for various cancers by providing a more precise imaging technique.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
* Age ≥18 years, regardless of gender;
* No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;
* Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study;
* Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form.

Exclusion Criteria:

* Known allergy to injection or its excipients;
* Severe liver or renal dysfunction;
* Claustrophobia or other psychiatric disorders;
* History of other malignant tumors;
* Participation in another clinical trial within 30 days prior to PET/CT scan;
* Pregnant or breastfeeding women;
* Refusal to participate or request for withdrawing from the clinical study;
* Other conditions deemed unsuitable for inclusion by investigator.

Where it's running

• Zhongnan Hospital of Wuhan University
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Yong He, MD, PhD — Zhongnan Hospital
• Study coordinator: Yong He, MD, PhD
• Email: vincentheyong@163.com
• Phone: +86-27-67812698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

• FAP-targeted PET and near-infrared fluorescence imaging for resectable non-small cell lung cancer

  We are testing whether FAP-targeted PET and near-infrared fluorescence can help find residual tumor and guide surgery in people with stage II–IIIB resectable non-small cell lung cancer after neoadjuvant therapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07498933

• Monoclonal antibody treatment for advanced solid tumors

  This study is testing a new antibody treatment for people with advanced solid tumors to see if it is safe and effective on its own or when combined with another cancer drug.

  Recruiting at 4 sites Phase 1/2 OncoResponse, Inc. · Austin, Texas and 3 other locations · NCT06090266

• Using 68Ga-FAPI PET/CT to visualize malignant tumors

  This study is testing a new imaging method using a special agent to see if it can help doctors better spot and understand malignant tumors, especially in gastrointestinal cancers.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT05034146

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.